Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma

Autor: Damien Cohen, Sumantra Ghosh, Yusuke Shimakawa, Njie Ramou, Pierre Simon Garcia, Anaëlle Dubois, Clément Guillot, Nora Kakwata-Nkor Deluce, Valentin Tilloy, Geoffroy Durand, Catherine Voegele, Gibril Ndow, Umberto d'Alessandro, Céline Brochier-Armanet, Sophie Alain, Florence Le Calvez-Kelm, Janet Hall, Fabien Zoulim, Maimuna Mendy, Mark Thursz, Maud Lemoine, Isabelle Chemin

Publikováno v: JHEP Reports, Vol 2, Iss 5, Pp 100144- (2020)

Background & Aims: Although HBV is a major cause of death in Africa, its genetic variability has been poorly documented. This study aimed to address whether HBV genotype and surface gene variants are associated with HBV-related liver disease in The G

Externí odkaz: https://doaj.org/article/192d73219e2e497587415f6ef2ae2755

Clinical utility of the 'Determine HBsAg' Point-of-Care Test for Diagnosis of Hepatitis B Surface Antigen in Africa

Autor: Amie Ceesay, Maud Lemoine, Damien Cohen, Isabelle Chemin, Gibril Ndow

Publikováno v: Expert review of molecular diagnostics. 22(5)

Introduction: Chronic infection with hepatitis B virus (HBV) is a leading cause of morbidity and death, especially in sub-Saharan Africa (SSA), where approximately 60 million adults are infected. More than 90% of these patients are unaware of their H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ceb2bdd0d418346971cfbb406d13598
https://pubmed.ncbi.nlm.nih.gov/35574686

Hepatitis B Virus Genotype Study in West Africa Reveals an Expanding Clade of Subgenotype A4

Autor: Amina Sow-Sall, Masashi Mizokami, Gora Lo, Flor H. Pujol, Fabien Zoulim, Coumba Toure-Kane, Damien Cohen, Kunikazu Hoshino, Isabelle Chemin, Rayana Maryse Toyé, Maud Lemoine

Publikováno v: Microorganisms
Microorganisms, Vol 9, Iss 623, p 623 (2021)

Hepatitis B virus (HBV) classification comprises up to 10 genotypes with specific geographical distribution worldwide, further subdivided into 40 subgenotypes, which have different impacts on liver disease outcome. Though extensively studied, the cla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac26c64b440af0cfd81ccac4f6daaad1
http://europepmc.org/articles/PMC8002614

Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma

Autor: Fabien Zoulim, Pierre Simon Garcia, Valentin Tilloy, Saunab Ghosh, Yusuke Shimakawa, Maud Lemoine, Janet Hall, Céline Brochier-Armanet, Njie Ramou, Anaëlle Dubois, Nora Kakwata-Nkor Deluce, Damien Cohen, Clément Guillot, Sophie Alain, Geoffroy Durand, Isabelle Chemin, Maimuna Mendy, Mark Thursz, Florence Le Calvez-Kelm, Umberto D'Alessandro, Catherine Voegele, Gibril Ndow

Publikováno v: JHEP Reports Innovation in Hepatology
JHEP Reports Innovation in Hepatology, 2020, 2 (5), pp.100144. ⟨10.1016/j.jhepr.2020.100144⟩
JHEP Reports
JHEP Reports Innovation in Hepatology, Elsevier, 2020, 2 (5), pp.100144. ⟨10.1016/j.jhepr.2020.100144⟩
JHEP Reports, Vol 2, Iss 5, Pp 100144-(2020)

Background & Aims Although HBV is a major cause of death in Africa, its genetic variability has been poorly documented. This study aimed to address whether HBV genotype and surface gene variants are associated with HBV-related liver disease in The Ga

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d18ee556097da0e4bbc621215f66628f
https://hal-pasteur.archives-ouvertes.fr/pasteur-03697731/document

PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles’ heel?

Autor: Pierre Saintigny, Nadim Fares, Aurélie Cartier, Joël Lachuer, Hector Hernandez-Vargas, Anne Wierinckx, Vincent Puard, Anaëlle Dubois, Anne Schnitzler, Alexia Paturel, Janick Selves, Janet Hall, Bérengère Ouine, Isabelle Chemin, Brigitte Bancel, Phillippe Merle, Ivan Bièche, Laetitia Gerossier, Leanne de Koning, Damien Cohen

Publikováno v: Clinics and Research in Hepatology and Gastroenterology. 45:101553

Background A promising avenue for cancer treatment is exacerbating the deregulation of the DNA repair machinery that would normally protect the genome. To address the applicability of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) combined wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86005159c0c91d3f44d52f2c8a4f9a0e
https://doi.org/10.1016/j.clinre.2020.09.014